Learn More >

Ministry Status: Activation Status

Drugs and Devices Division

EO Decisions and CED Recommendations

The information below is intended only to provide the recommendations and rationale from the Committee to Evaluate Drugs (CED) and the Executive Officer decisions regarding the listing of products on the Formulary, funding of cancer drugs through the New Drug Funding Program, funding through the Exceptional Access Program, or funding through the Special Drugs Program.

For further details on what types of information is provided, please refer to the Transparency of the Drug Review Process.

Do not rely upon any of the information provided on this site for medical diagnosis or treatment. Please consult your primary health care provider about any personal health concerns. This website does not provide any medical diagnosis, symptom assessment, health counseling or medical opinion for individual users. The information contained on this site is intended for information purposes only and does not constitute medical advice for patients. For more detailed information on prescription drugs, please consult a qualified healthcare professional.

Brand Name Generic Name Date Published
Abraxane nab-paclitaxel April 2010
Aclasta – osteoporosis zoledronic acid January 2009
Actonel 75mg and 150mg risedronate sodium July 2010
Actonel Plus Calcium risedronate sodium/calcium carbonate July 2007
Adcetris - Hodgkin lymphoma brentuximab May 2015
Adcirca tadalafil May 2011
Adderall XR mixed amphetamine salts October 2009
Advagraf tacrolimus (extended-release) April 2010
Afinitor everolimus May 2011
Aldara imiquimod February 2010
Alimta – non-small cell lung cancer pemetrexed August 2008
Alimta - MPM pemetrexed July 2007
Altace 15mg capsule ramipril 15mg capsule January 2008
Altace HCT ramipril/hydrochlorothiazide June 2008
Altace Plus Felodipine ramipril/felodipine October 2007
Alvesco ciclesonide May 2008
Androderm 24.3 mg transdermal patch testosterone May 2015
Aricept RDT donepezil rapidly dissolving tablet June 2008
Aromasin – early breast cancer exemestane August 2008
Atacand candesarten cilexetil February 2010
Avalide irbesartan/hydrochlorothiazide October 2007
Avastin – GBM re-evaluation bevacizumab January 2014
Avastin – GBM bevacizumab October 2011
Avastin - for metastatic colorectal cancer bevacizumab September 2009
Azilect rasagiline August 2010
Biphentin methylphenidate extended release February 2010
Caelyx – recurrent ovarian cancer pegylated liposomal doxorubicin October 2007
Caripul epoprostenol May 2015
Champix varenicline November 2012
Cipralex escitalopram November 2008
Celsentri maraviroc October 2009
Clindoxyl 1%/ benzoyl peroxide 3% gel clindamycin May 2015
Combigan 10mL – new package size brimonidine/timolol November 2008
Cubicin daptomycin November 2009
Combination treatment for Pulmonary Arterial Hypertension (PAH)   July 2010
Cymbalta for DPN duloxetine for DPN August 2010
DDAVP Melt desmopressin May 2008
Denavir penciclovir June 2008
Diovan valsartan July 2007
Diovan-HCT valsartan/ hydrochlorothiazide October 2009
Dovobet gel calcipotriol / betamethasone May 2015
Dovobet calcipotriol/betamethasone October 2008
Duragesic 12 fentanyl 12.5mcg/hr transdermal patch October 2007
Elaprase idursulfase May 2008
Eloxatin – adjuvant treatment of colorectal cancer oxaliplatin October 2008
Eloxatin – metastatic colorectal cancer oxaliplatin October 2008
Enablex darifenacin July 2007
Eprex - additional dosage forms epoetin alfa - additional dosage forms November 2009
Epuris isotretinoin May 2015
Erbitux – head & neck cancer cetuximab April 2011
Erbitux – metastatic colorectal cancer cetuximab April 2011
Esbriet pirfenidone May 2015
Exelon Patch rivastigmine patch October 2009
Exjade deferasirox March 2010
Faslodex fulvestrant April 2010
Femara letrozole January 2008
Fluanxol Depot flupenthixol decanoate February 2010
Fludara – CLL fludarabine tablet October 2011
Fosavance 70/140 alendronate-cholecalciferol July 2010
Fosavance alendronate/cholecalciferol July 2007
Fycompa perampanel May 2015
Gemzar – metastatic breast cancer gemcitabine hydrochloride August 2008
Genotropin somatropin May 2015
Gleevec – ALL imatinib January 2011
Gleevec - CML imatinib mesylate July 2007
Gleevec - GIST imatinib mesylate July 2007
Humalog Mix50 insulin lispro/insulin lispro protamine August 2010
Humira – psoriatic arthritis adalimumab October 2007
Hycamtin – small cell lung cancer topotecan August 2008
Hycamtin – recurrent ovarian cancer topotecan October 2007
Hypurin insulin porcine May 2008
Intelence etravirine March 2009
Invega paliperidone November 2009
Januvia sitagliptin March 2012
Jentadueto linagliptin / metformin May 2015
Kaletra pediatric tablet lopinavir / ritonavir March 2010
Lantus SoloStar insulin glargine August 2010
Lantus insulin glargine March 2009
Leukotriene Receptor Antagonists
(Singulair, Accolate)
leukotriene receptor antagonists
(montelukast, zafirlukast)
November 2010
Levemir Penfill insulin detemir August 2010
Linessa desogestrel/ethinyl estradiol January 2008
Long-Acting medications for Attention Deficit Hyperactivity Disorder (ADHD) long-acting medications for attention deficit hyperactivity disorder (ADHD) January 2011
Lucentis ranibizumab June 2008
MabCampath alemtuzumab August 2008
Mekinist trametinib May 2015
Metvix methyl aminolevulinate October 2011
Mezavant mesalamine (5-ASA) June 2010
Myozyme alglucosidase alfa December 2009
Nexavar – hepatocellular carcinoma sorafenib January 2009
Nexavar – metastatic renal cell carcinoma sorafenib October 2008
Nutropin AQ® NuSpin® 5 and 20 somatropin May 2015
Nuvaring etonogestrel / ethinyl estradiol February 2010
One-Alpha alfacalcidol November 2009
Omnaris ciclesonide November 2009
Orencia abatacept May 2011
OxyContin oxycodone hydrochloride July 2007
Pentasa 1 gram extended-release tablet 5-aminosalicylic acid May 2015
Perjeta pertuzumab / trastuzumab May 2015
Picato ingenol mebutate topical gel May 2015
Posanol posaconazole April 2009
Prolastin alpha1-proteinase inhibitor April 2011
Prezista darunavir January 2008
Ralivia tramadol hydrochloride ER June 2010
Rasilez aliskiren October 2009
Rebif initiation package interferon beta1a February 2010
Resultz isopropyl myristate April 2010
Revatio sildenafil July 2010
Revlimid lenalidomide May 2015
Revlimid – myelodysplastic syndrome lenalidomide April 2009
Rituxan – CLL rituximab October 2011
Rituxan – rheumatoid arthritis rituximab January 2009
Samsca tolvaptan May 2015
Seasonale levonorgestrel / ethinyl estradiol April 2009
Seroquel XR quetiapine fumarate June 2010
Sensipar cinacalcet December 2008
Simponi – ankylosing spondylitis golimumab April 2011
Simponi – psoriatic arthritis golimumab April 2011
Simponi – rheumatoid arthritis golimumab April 2011
Sprycel – ALL dasatinib January 2011
Sprycel – chronic myeloid leukemia dasatinib December 2008
Stalevo levodopa/ carbidopa/ entacapone October 2009
Sublinox zolpidem May 2015
Sutent – MRCC sunitinib May 2008
Sutent – GIST sunitinib October 2007
Taxol – recurrent ovarian cancer paclitaxel October 2007
Tecfidera dimethyl fumarate May 2015
Thelin sitaxsentan January 2011
Torisel temsirolimus May 2011
Tridural tramadol hydrochloride ER June 2010
Trisenox arsenic trioxide May 2015
Trosec trospium chloride August 2008
Truvada emtricitabine/Tenofovir disoproxil fumarate June 2008
Tysabri natilizumab February 2011
Vantas histrelin acetate February 2010
Vectibix panitumumab February 2009
Vfend voriconazole October 2007
Vidaza azacitidine May 2011
Volibris ambrisentan July 2010
Votrient pazopanib May 2015
Xeloda – gastric cancer capecitabine August 2008
Xeloda capecitabine (as component of CAPOX regimen) October 2009
Xarelto rivaroxaban June 2010
Yasmin drospirenone/ethinyl estradiol January 2008
Zytiga abiraterone May 2015
Zytram XL tramadol hydrochloride XL June 2010

For More Information

Call ServiceOntario, Infoline at:
1–866–532–3161 (Toll–free)
In Toronto, (416) 314–5518
TTY 1–800–387–5559.
In Toronto, TTY (416)327–4282
Hours of operation: Monday to Friday, 8:30am – 5:00pm

  • Connect With Us
Facebook Twitter YouTube RSS